Therefore, due to its multi-targeted effects, inhibiting HSP90 in the MYCN-amplified human IMR-32 cell line would cripple all of its critical, tumor-promoting functions, thereby yielding tangible therapeutic effects on these malignant cells. Here, HSP90AA1 is linked to neoplasm.